Compare GIB & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GIB | NBIX |
|---|---|---|
| Founded | 1976 | 1992 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.8B | 13.2B |
| IPO Year | 1999 | 1996 |
| Metric | GIB | NBIX |
|---|---|---|
| Price | $62.19 | $164.01 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 22 |
| Target Price | $112.00 | ★ $180.91 |
| AVG Volume (30 Days) | 418.6K | ★ 1.1M |
| Earning Date | 04-29-2026 | 05-05-2026 |
| Dividend Yield | ★ 0.70% | N/A |
| EPS Growth | N/A | ★ 41.95 |
| EPS | N/A | ★ 1.91 |
| Revenue | N/A | ★ $161,626,000.00 |
| Revenue This Year | $8.33 | $24.73 |
| Revenue Next Year | $2.96 | $13.14 |
| P/E Ratio | ★ $13.59 | $87.09 |
| Revenue Growth | N/A | ★ 977.51 |
| 52 Week Low | $59.63 | $122.14 |
| 52 Week High | $106.68 | $169.57 |
| Indicator | GIB | NBIX |
|---|---|---|
| Relative Strength Index (RSI) | 37.64 | 58.86 |
| Support Level | $61.35 | $153.96 |
| Resistance Level | $70.68 | $169.57 |
| Average True Range (ATR) | 1.95 | 4.68 |
| MACD | -0.42 | -0.44 |
| Stochastic Oscillator | 29.02 | 61.36 |
CGI is a Canada-based IT-services provider with an embedded position in North America and Europe. The company is one of the major IT suppliers to different levels of government around the world. It offers a broad portfolio of services such as consulting, systems integration, application maintenance, and business process services to governments and the private sector. With offices in over 40 countries, CGI follows a balanced global delivery model with most consultants in client proximity.
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.